S&P Futures
4,261.75+5.75(+0.14%)Dow Futures
34,194.00+112.00(+0.33%)Nasdaq Futures
14,381.75+27.50(+0.19%)
Akebia Therapeutics, Inc. (AKBA)
Pre-Market: 06:45AM EDT
Chart Events
Performance Outlook
| Previous Close | 3.9600 |
| Open | 3.9300 |
| Bid | 4.1200 x 21500 |
| Ask | 0.0000 x 4000 |
| Day's Range | 3.9200 - 4.1800 |
| 52 Week Range | 2.0900 - 13.7100 |
| Volume | 4,659,213 |
| Avg. Volume | 3,513,904 |
| Market Cap | 669.281M |
| Beta (5Y Monthly) | 1.75 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.7090 |
| Earnings Date | Aug 09, 2021 - Aug 13, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.57 |
- Newsfile
Investigation Alert: The Schall Law Firm Announces it is Investigating Claims Against Akebia Therapeutics, Inc. and Encourages Investors Who Formerly Held Shares of Keryx Biopharmaceuticals (KERX) to Contact the Firm
Los Angeles, California--(Newsfile Corp. - June 18, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Akebia Therapeutics, Inc. ("Akebia" or "the Company") (NASDAQ: AKBA) who formerly held shares of Keryx Biopharmaceuticals, Inc. (KERX) for violations of the securities laws.If you are a shareholder, click here to participate.We also encourage you to contact Brian Schall of the Schall Law Firm, ...
- Simply Wall St.
Reflecting on Akebia Therapeutics' (NASDAQ:AKBA) Share Price Returns Over The Last Year
Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shareholders should be happy to see the share price up 10% in the last month...
- Benzinga
Cyclerion Out-Licenses Praliciguat to Akebia, Announces $18M Capital Raise
Cyclerion Therapeutics Inc (NASDAQ: CYCN) has entered into an exclusive, global license agreement with Akebia Therapeutics Inc (NASDAQ: AKBA) for the development and commercialization of praliciguat. Under the terms of the agreement, Akebia will be solely responsible for the research, development, and commercialization of praliciguat globally. Cyclerion is eligible to receive up to $225 million in pre-commercial milestones, including up to $15 million in the first 18 months. Total potential futu
